• 654 引文
  • 13 h-指數
19962019
如果您對這些純文本內容做了任何改變,很快就會看到。

個人檔案

學歷

  • 中山醫學院醫學系學士

經歷

  • 1992年08月 ~迄今 胃腸肝膽科醫師

指紋 查看啟用 Pin-Nan Cheng 的研究主題。這些主題標籤來自此人的作品。共同形成了獨特的指紋。

  • 29 類似的檔案
Chronic Hepatitis C Medicine & Life Sciences
Hepacivirus Medicine & Life Sciences
Chronic Hepatitis B Medicine & Life Sciences
Virus Diseases Medicine & Life Sciences
Ribavirin Medicine & Life Sciences
Genotype Medicine & Life Sciences
Hepatitis B virus Medicine & Life Sciences
Taiwan Medicine & Life Sciences

網絡 國家層面的近期外部合作。點選圓點深入探索詳細資料。

研究成果 1996 2019

  • 654 引文
  • 13 h-指數
  • 64 Article
  • 1 Review article

An Open-Label, Randomized, Active-Controlled Trial of 8 Versus 12 Weeks of Elbasvir/Grazoprevir for Treatment-Naive Patients With Chronic Hepatitis C Genotype 1b Infection and Mild Fibrosis (EGALITE Study): Impact of Baseline Viral Loads and NS5A Resistance-Associated Substitutions

Huang, C. F., Hung, C. H., Cheng, P. N., Bair, M. J., Huang, Y. H., Kao, J. H., Hsu, S. J., Lee, P. L., Chen, J. J., Chien, R. N., Peng, C. Y., Lin, C. Y., Hsieh, T. Y., Cheng, C. H., Dai, C. Y., Huang, J. F., Chuang, W. L. & Yu, M. L., 2019 七月 19, 於 : The Journal of infectious diseases. 220, 4, p. 557-566 10 p.

研究成果: Article

Chronic Hepatitis C
Viral Load
Fibrosis
Randomized Controlled Trials
Genotype
1 引文 (Scopus)
Vascular Stiffness
Antiviral Agents
Fibrosis
Chronic Hepatitis C
Blood Pressure
2 引文 (Scopus)

Efficacy and safety of 12 weeks of daclatasvir, asunaprevir plus ribavirin for HCV genotype-1b infection without NS5A resistance-associated substitutions

Yu, M. L., Hung, C. H., Huang, Y. H., Peng, C. Y., Lin, C. Y., Cheng, P-N., Chien, R. N., Hsu, S. J., Liu, C. H., Huang, C. F., Su, C. W., Huang, J. F., Liu, C. J., Kao, J. H., Chuang, W. L., Chen, P. J. & Chen, D. S., 2019 二月 1, 於 : Journal of the Formosan Medical Association. 118, 2, p. 556-564 9 p.

研究成果: Article

開啟存取
Ribavirin
Genotype
Safety
Infection
Galectin 3
2 引文 (Scopus)
開啟存取
Russia
Hepacivirus
Genotype
Safety
Infection